Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s

AbbVie's SKYRIZI has shown sustained endoscopic outcomes through 144 weeks in Crohn's disease patients, with a 74.5% fistula resolution rate at five years, according to new Phase 3 AFFIRM data. Additionally, real-world data for RINVOQ indicate successful disease control in patients with advanced Crohn's disease. The findings were presented at the American College of Gastroenterology 2026 Annual Scientific Meeting, underscoring AbbVie's commitment to addressing inflammatory bowel disease complexities.